Clinical Trials
3 trialsNCT06252584 2024-02-09
AML-VAC-XS15
University Hospital Tuebingen
Phase 1 Not yet recruiting
NCT02802943 2022-11-28
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
University Hospital Tuebingen
Phase 2 Completed
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated